Lantern Pharma Inc.
Price Action
Technical Summary
CONSOLIDATINGLantern Pharma Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 86), indicating clear outperformance against the broad market. Earnings growth of 29% provides fundamental context to the price action. However, price is extended 25% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.79 | +1.87% | ABOVE |
| 50 SMA | $3.09 | +24.98% | ABOVE |
| 100 SMA | $2.74 | +40.99% | ABOVE |
| 150 SMA | $2.96 | +30.19% | ABOVE |
| 200 SMA | $3.22 | +19.79% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LTRN in an uptrend right now?
LTRN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is LTRN overbought or oversold?
LTRN's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is LTRN outperforming the market?
LTRN has a Relative Strength (RS) Rating of 86 out of 99. Yes, LTRN is a market leader, outperforming 86% of all stocks over the past 12 months.
Where is LTRN in its 52-week range?
LTRN is trading at $3.86, which is 67% of its 52-week high ($5.74) and 59% above its 52-week low ($1.11).
How volatile is LTRN?
LTRN has a Beta of 2.81 and 52-week volatility of 99%. It's more volatile than the S&P 500 - expect bigger swings.